Cardiac slices as a predictive tool for arrhythmogenic potential of drugs and chemicals

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 12, 2010, Pages 1461-1475

  Meyer, Thomas ^a   Stuerz, Katharina ^a   Guenther, Elke ^a   Edamura, Mitsuhiro ^a   Kraushaar, Udo ^a  

^a MULTI CHANNEL SYSTEMS MCS GMBH   (Germany)

Author keywords

Array; Cardiac; Electrophysiology; Microelectrode; Safety pharmacology; Slice

Indexed keywords

DOFETILIDE; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL STIMULATING AGENT; RILMACALIM; UNCLASSIFIED DRUG;

ARRHYTHMOGENESIS; CARDIAC SLICE; CELL ASSAY; DRUG DETERMINATION; DRUG SAFETY; HEART; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART PROARRHYTHMIA; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; ION CURRENT; ISOLATED HEART; LIGAND BINDING; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; TISSUE LEVEL; TISSUE SLICE; VOLTAGE CLAMP;

ANIMALS; ARRHYTHMIAS, CARDIAC; DRUG DESIGN; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART; HUMANS; MICROELECTRODES; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; PHARMACEUTICAL PREPARATIONS;

EID: 78649232863     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.526601     Document Type: Review

References (126)

1. Kinter LB, Siegl PKS, Bass AS. New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age. J Pharmacol Toxicol Methods 2004;49(3):153-8
2. Williams PD. The role of pharmacological profiling in safety assessment. Regul Toxicol Pharmacol 1990;12(3 Pt 1):238-52
3. S7B: the nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; 2005. p. 61133-4
4. Sedmera D, McQuinn T. Embryogenesis of heart muscle. Heart Fail Clin 2008;4(3):235-45
5. Forleo GB, Tondo C. Atrial fibrillation: cure or treat? Ther Adv Cardiovasc Dis 2009;3(3):187-96
6. Valentin J-P. Reducing QT liability and proarrhythmic risk in drug discovery and development. Br J Pharmacol 2010;159(1):5-11
7. Chan ASY, Isbister GK, Kirkpatrick CMJ, Duffull SB. Assessing risk of a prolonged QT interval-a survey of emergency physicians. Int J Emerg Med 2008;1(1):35-41
8. Christensen TF, Tarnow L, Randlov J, et al. QT interval prolongation during spontaneous episodes of hypoglycaemia in type 1 diabetes: the impact of heart rate correction. Diabetologia 2010;53(9):2036-41
9. Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001;24(8):575-85
10. Ponte ML, Keller GA, Di Girolamo G. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf 2010;5(1):44-53
11. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms review of cardiac arrhythmias. Cell 2001;104:569-80
12. Sanguinetti MC. HERG1 channelopathies. Pflugers Arch 2010;460(2):265-76
13. Kass RS, Moss AJ. Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J Clin Invest 2003;112(6):810-15
14. Bains W, Basman A, White C. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog Biophys Mol Biol 2004;86(2):205-33
15. Diaz GJ, Daniell K, Leitza ST, et al. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: comparison of intact cell and membrane preparations and effects of altering [K+]o. J Pharmacol Toxicol Methods 2010;50(3):187-99
16. Finlayson K, Turnbull L, January CT, et al. [3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol 2001;430(1):147-8
17. Chiu PJS, Marcoe KF, Bounds SE, et al. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci 2004;95(3):311-19
18. Daniel S, Malkowitz L, Wang HC, et al. Screening for potassium channel modulators by a high through-put 86-rubidium efflux assay in a 96-well microtiter plate. J Pharmacol Methods 1991;25(3):185-93
19. Gill S, Gill R, Lee SS, et al. Flux assays in high throughput screening of ion channels in drug discovery. Assay Drug Dev Technol 2003;1(5):709-17
20. Rezazadeh S, Hesketh JC, Fedida D. Rb+ Flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ Efflux assay. J Biomol Screen 2004;9(7):588-97
21. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97(22):12329-33
22. Kongsamut S, Kang J, Chen X-L, et al. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002;450(1):37-41
23. Castelletti L, Memo M, Missale C, et al. Potassium channels involved in the transduction mechanism of dopamine D2 receptors in rat lactotrophs. J Physiol 1989;410:251-65
24. Miller SS, Edelman JL. Active ion transport pathways in the bovine retinal pigment epithelium. J Physiol 1990;424:283-300
25. Dick E, Rajamohan D, Ronksley J, Denning C. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans 2010;38(4):1037-45
26. Muller M, Fleischmann BK, Selbert S, et al. Selection of ventricular-like cardiomyocytes from ES cells in vitro. FASEB J 2000;14(15):2540-8
27. Pekkanen-Mattila M, Chapman H, Kerkela E, et al. Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype. Exp Biol Med (Maywood) 2010;235(4):522-30
28. Sartiani L, Bettiol E, Stillitano F, et al. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 2007;25(5):1136-44
29. Tanaka T, Tohyama S, Murata M, et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 2009;385(4):497-502
30. Zhu W-Z, Santana LF, Laflamme MA. Local control of excitation-contraction coupling in human embryonic stem cell-derived cardiomyocytes. PLoS ONE 2009;4(4):e5407
31. Zwi L, Caspi O, Arbel G, et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 2009;120(15):1513-23
32. Guo L, Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Methods 2005;52(1):123-35
33. Kiss L, Bennett PB, Uebele VN, et al. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol 2003;1(1 Pt 2):127-35
34. Kutchinsky J, Friis S, Asmild M, et al. Characterization of potassium channel modulators with QPatch automated patch-clamp technology: system characteristics and performance. Assay Drug Dev Technol 2003;1(5):685-93
35. Robertson GA, Warmke JM, Ganetzky B. Potassium currents expressed from Drosophila and mouse eag cDNAs in Xenopus oocytes. Neuropharmacology 1996;35(7):841-50
36. Witchel HJ, Milnes JT, Mitcheson JS, Hancox JC. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Methods 2002;48(2):65-80
37. Baldi L, Muller N, Picasso S, et al. Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol Prog 2005;21(1):148-53
38. Lee YY, Yap MGS, Hu W-S, Wong KTK. Low-glutamine fed-batch cultures of 293-HEK serum-free suspension cells for adenovirus production. Biotechnol Prog 2003;19(2):501-9
39. Powell T, Twist VW. A rapid technique for the isolation and purification of adult cardiac muscle cells having respiratory control and a tolerance to calcium. Biochem Biophys Res Commun 1976;72(1):327-33
40. Carlsson L. In vitro and in vivo models for testing arrhythmogenesis in drugs. J Intern Med 2006;259(1):70-80
41. Drici MD, Wang WX, Liu XK, et al. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 1998;18(6):477-81
42. Bugaisky LB, Zak R. Differentiation of adult rat cardiac myocytes in cell culture. Circ Res 1989;64(3):493-500
43. Mitcheson JS, Hancox JC, Levi AJ. Cultured adult cardiac myocytes: future applications, culture methods, morphological and electrophysiological properties. Cardiovasc Res 1998;39(2):280-300
44. Viero C, Kraushaar U, Ruppenthal S, et al. A primary culture system for sustained expression of a calcium sensor in preserved adult rat ventricular myocytes. Cell Calcium 2008;43(1):59-71
45. Volz A, Piper HM, Siegmund B, Schwartz P. Longevity of adult ventricular rat heart muscle cells in serum-free primary culture. J Mol Cell Cardiol 1991;23(2):161-73
46. Meiry G, Reisner Y, Feld Y, et al. Evolution of action potential propagation and repolarization in cultured neonatal rat ventricular myocytes. J Cardiovasc Electrophysiol 2001;12(11):1269-77
47. Tung L, Zhang Y. Optical imaging of arrhythmias in tissue culture. J Electrocardiol 2006;39(4 Suppl): S2-6
48. Metzger JM, Lin WI, Samuelson LC. Vital staining of cardiac myocytes during embryonic stem cell cardiogenesis in vitro. Circ Res 1996;78(4):547-52
49. Sachinidis A, Kolossov E, Fleischmann BK, Hescheler J. Generation of cardiomyocytes from embryonic stem cells experimental studies. Herz 2002;27(7):589-97
50. Yuasa S, Fukuda K. Recent advances in cardiovascular regenerative medicine: the induced pluripotent stem cell era. Expert Rev Cardiovasc Ther 2008;6(6):803-10
51. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009;104(4):e30-41-e30-41
52. Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev 2010;6(1):108-20
53. Braam SR, Tertoolen L, van de Stolpe A, et al. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 2010;4(2):107-16
54. Caspi O, Itzhaki I, Kehat I, et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev 2009;18(1):161-72
55. Langendorff O. Untersuchungen am uberlebenden Saugethierherzen. Pflugers Arch 1895;61(6):291-332
56. Broadley KJ. The Langendorff heart preparation-Reappraisal of its role as a research and teaching model for coronary vasoactive drugs. J Pharmacol Methods 1979;2(2):143-56
57. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58(1):32-45
58. Dennis A, Wang L, Wan X, Ficker E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 2007;35:1060-3
59. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation 1996;94(11):2968-74
60. Chartrand E, Arnold AA, Gravel A, et al. Potential role of the membrane in hERG channel functioning and drug-induced long QT syndrome. Biochim Biophys Acta 2010;1798(9):1651-62
61. Wynia-Smith SL, Gillian-Daniel AL, Satyshur KA, Robertson GA. hERG gating microdomains defined by S6 mutagenesis and molecular modeling. J Gen Physiol 2008;132(5):507-20
62. Barth AS, Tomaselli GF. Cardiac metabolism and arrhythmias. Circ Arrhythm Electrophysiol 2009;2(3):327-35
63. Hoffmann P, Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 2010;53(2):87-105
64. Hayes E, Pugsley MK, Penz WP, et al. Relationship between QaT and RR intervals in rats, guinea pigs, rabbits, and primates. J Pharmacol Toxicol Methods 1994;32(4):201-7
65. Podrid PJ, Kowey PR. Cardiac arrhythmia: mechanisms, diagnosis, and management: Lippincott Williams & Wilkins; 2001
66. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001;103(15):2004-13
67. Oosterhoff P, Oros A, Vos MA. Beat-to-beat variability of repolarization: a new parameter to determine arrhythmic risk of an individual or identify proarrhythmic drugs. Anadolu Kardiyol Derg 2007;7(Suppl 1):73-8
68. Batey AJ, Doe CP. A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs. J Pharmacol Toxicol Methods 2002;48(1):11-9
69. Thomsen MB, Oros A, Schoenmakers M, et al. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc Res 2007;73(3):521-30
70. Burashnikov A, Shimizu W, Antzelevitch C. Fever accentuates transmural dispersion of repolarization and facilitates development of early afterdepolarizations and torsade de pointes under long-QT Conditions. Circ Arrhythmia Electrophysiol 2008;1(3):202-8
71. Song Y, Belardinelli L. ATP promotes development of afterdepolarizations and triggered activity in cardiac myocytes. Am J Physiol 1994;267(5 Pt 2): H2005-11-H-11
72. Yan G-X, Antzelevitch C. Cellular basis for the electrocardiographic J Wave Circ 1996;93(2):372-9
73. Bowlby MR, Peri R, Zhang H, Dunlop J. hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk. Curr Drug Metab 2008;9(9):965-70
74. Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol 2008;154(7):1502-7
75. Gongadze N, Kezeli T, Antelava N. Prolong QT interval and "torsades de pointes" associated with different group of drugs. Georgian Med News 2007; (153):45-9
76. Valentin J-P, Hoffmann P, De Clerck F, et al. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods 2004;49(3):171-81
77. Burnashev NA, Edwards FA, Verkhratskii AN. The use of thin slices of myocardium for recording the currents across single ion channels. Fiziol Zh 1991;37(2):119-22
78. de Boer TP, Camelliti P, Ravens U, Kohl P. Myocardial tissue slices: organotypic pseudo-2D models for cardiac research & development. Future Cardiol 2009;5(5):425-30
79. Yasuhara S, Takaki M, Kikuta A, et al. Myocardial VO2 of mechanically unloaded contraction of rat ventricular slices measured by a new approach. Am J Physiol 1996;270(3 Pt 2): H1063-H70-H-H70
80. Han J, Kim N, Joo H, Kim E. Ketamine abolishes ischemic preconditioning through inhibition of KATP channels in rabbit hearts. Am J Physiol Heart Circ Physiol 2002;283(1):H13-21-H13-21
81. Pillekamp F, Halbach M, Reppel M, et al. Neonatal murine heart slices. A robust model to study ventricular isometric contractions. Cell Physiol Biochem 2007;20(6):837-46
82. Hirota H. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999;97(2):189-98
83. Witt CC, Gerull B, Davies MJ, et al. Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C. J Biol Chem 2001;276(7):5353-9
84. Du C-K, Morimoto S, Nishii K, et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res 2007;101(2):185-94
85. Stuerz K, Guenther E, Reppel M, et al. Organotypic ventricular heart slices of guinea pig and pig to test for drug side effects. Conference Proceedings of the 7th International Meeting on Substrate-Integrated Microelectrode Arrays; 2009: BIOPRO Baden-Wurttemberg GmbH, Stuttgart, 2010;2009
86. Habeler W, Pouillot S, Plancheron A, et al. An in vitro beating heart model for long-term assessment of experimental therapeutics. Cardiovasc Res 2009;81(2):253-9
87. Wenzel J, Brandenburger M, Bogdan R, et al. Funktionelle humane adulte ventrikulare Herzschnitte - Entwicklung eines neuen Modellsystems. Clin Res Cardiol 2009;98(Suppl 2): P87
88. Adhyapak SM, Parachuri VR. Architecture of the left ventricle: insights for optimal surgical ventricular restoration. Heart Fail Rev 2010;15(1):73-83
89. Sicouri S, Glass A, Ferreiro M, Antzelevitch C. Transseptal dispersion of repolarization and its role in the development of Torsade de Pointes arrhythmias. J Cardiovasc Electrophysiol 2010;21(4):441-7
90. Habeler W, Peschanski M, Monville C. Organotypic heart slices for cell transplantation and physiological studies. Organogenesis 2009;5(2):62-6
91. Xu B, Jacquir S, Binczak S, et al. MEA-aided investigtion of cardiac arrhythmia induced by electrial stimulation. In: Stett A, editor, 7th edition. Int Meeting on Substrate-Integrated Microelectrode Arrays: BIOPRO edition; 2010
92. Davidenko JM, Pertsov AV, Salomonsz R, et al. Stationary and drifting spiral waves of excitation in isolated cardiac muscle. Nature 1992;355(6358):349-51
93. Antzelevitch C. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 2007;9(Suppl 4): iv4-15
94. Halbach M, Pillekamp F, Brockmeier K, et al. Ventricular slices of adult mouse hearts-a new multicellular in vitro model for electrophysiological studies. Cell Physiol Biochem 2006;18(1-3): 1-8
95. International Conference on Harmonisation The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; 2005
96. Bussek A, Wettwer E, Christ T, et al. Tissue slices from adult mammalian hearts as a model for pharmacological drug testing. Cell Physiol Biochem 2009;24(5-6): 527-36
97. Terstappen GC. Nonradioactive rubidium ion efflux assay and its applications in drug discovery and development. Assay Drug Dev Technol 2004;2(5):553-9
98. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269(5220):92-5
99. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81(2):299-307
100. Comley J. Automated patch clamping, setting a new standard for early hERG. Drug Discov World 2005;6:62-79
101. Lawrence CL, Pollard CE, Hammond TG, Valentin JP. Nonclinical proarrhythmia models: predicting Torsades de Pointes. J Pharmacol Toxicol Methods 2005;52(1):46-59
102. Shiotani M, Harada T, Abe J, et al. Practical application of guinea pig telemetry system for QT evaluation. J Toxicol Sci 2005;30(3):239-47
103. Lopez-Santiago LF, Meadows LS, Ernst SJ, et al. Sodium channel Scn1b null mice exhibit prolonged QT and RR intervals. J Mol Cell Cardiol 2007;43(5):636-47
104. van Ginneken AC, Fijnvandraat AC. Electrophysiological properties of embryonic stem cells during differentiation into cardiomyocyte-like cell types. Methods Mol Biol 2007;403:211-17
105. Kuzmenkin A, Liang H, Xu G, et al. Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro. FASEB J 2009;23(12):4168-80
106. Pillekamp F, Reppel M, Brockmeier K, Hescheler J. Impulse propagation in late-stage embryonic and neonatal murine ventricular slices. J Electrocardiol 2006;39(4):425 e1-4
107. Ghais NS, Zhang Y, Grace AA, Huang CL. Arrhythmogenic actions of the Ca2+ channel agonist FPL-64716 in Langendorff-perfused murine hearts. Exp Physiol 2009;94(2):240-54
108. Smyrnias I, Mair W, Harzheim D, et al. Comparison of the T-tubule system in adult rat ventricular and atrial myocytes, and its role in excitation-contraction coupling and inotropic stimulation. Cell Calcium 2010;47(3):210-23
109. Webb JL, Saunders PR, Thienes CH. The metabolism of the heart in relation to drug action; the action of metabolic inhibitors on rat heart slice respiration. Arch Biochem 1949;22(3):458-66
110. Farkas A, Curtis MJ. Does QT widening in the Langendorff-perfused rat heart represent the effect of repolarization delay or conduction slowing? J Cardiovasc Pharmacol 2003;42(5):612-21
111. Daleau P, Turgeon J. Triamterene inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Circ Res 1994;74(6):1114-20
112. Watson-Wright WM, Armour JA, Johnstone DE, Wilkinson M. Myocardial slice: a physiological approach to beta-adrenergic ([3H] CGP-12177) receptor binding in hamster and guinea pig heart. J Pharmacol Methods 1989;22(1):37-47
113. Padrini R, Speranza G, Nollo G, et al. Adaptation of the QT interval to heart rate changes in isolated perfused guinea pig heart: influence of amiodarone and D-sotalol. Pharmacol Res 1997;35(5):409-16
114. Diness TG, Yeh YH, Qi XY, et al. Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Cardiovasc Res 2008;79(1):61-9
115. Han X, Ferrier GR. Transient inward current is conducted through two types of channels in cardiac Purkinje fibres. J Mol Cell Cardiol 1996;28(10):2069-84
116. Tice BM, Rodriguez B, Eason J, Trayanova N. Mechanistic investigation into the arrhythmogenic role of transmural heterogeneities in regional ischaemia phase 1A. Europace 2007;9(Suppl 6): vi46-58
117. Cheng HC, Incardona J. Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts. J Pharmacol Toxicol Methods 2009;60(2):174-84
118. Vandermolen DT, Muntz KH, Buja LM. Quantification of beta-adrenergic receptors in canine cardiac myocytes using autoradiography and an internal standard. Lab Invest 1986;54(3):353-9
119. Giles RW, Eikens E, Paoloni HJ, et al. Effects of catecholamines on the coronary circulation in the Langendorff-type transplanted dog heart. Cardiovasc Res 1975;9(6):779-87
120. Harding SE, O'Gara P, Jones SM, et al. Species dependence of contraction velocity in single isolated cardiac myocytes. Cardioscience 1990;1(1):49-53
121. Carmeliet E. Electrophysiological effects of encainide on isolated cardiac muscle and Purkinje fibers and on the Langendorff-perfused guinea-pig heart. Eur J Pharmacol 1980;61(3):247-62
122. Schwanke K, Wunderlich S, Reppel M, et al. Generation and characterization of functional cardiomyocytes from rhesus monkey embryonic stem cells. Stem Cells 2006;24(6):1423-32
123. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131(5):861-72
124. Nanthakumar K, Jalife J, Masse S, et al. Optical mapping of Langendorff-perfused human hearts: establishing a model for the study of ventricular fibrillation in humans. Am J Physiol Heart Circ Physiol 2007;293(1):H875-80
125. Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 2002;5(1):116-26
126. Meyer T, Sartipy P, Blind F, et al. New cell models and assays in cardiac safety profiling. Expert Opin Drug Metab Toxicol 2007;3(4):507-17